期刊文献+

肿瘤专科医院2004-2006年肿瘤治疗相关用药现状与趋势分析 被引量:3

Current status and trend of drug usage for neoplasm treatment in a tumor hospital during 2004~2006
在线阅读 下载PDF
导出
摘要 目的了解肿瘤药物治疗的用药情况,探讨肿瘤专科医院用药的特点和发展趋势。方法采用金额排序法对2004-2006年肿瘤治疗相关用药使用情况进行统计分析。结果2004-2006年肿瘤治疗相关用药购药金额分别为4 191万、5 292万、5 244万元,占全部西药的比例分别为47.0%、55.1%、52.1%,抗肿瘤药2005年较2004年金额增长27.2%,2006年由于受药品降价的影响而出现负增长,3年中各亚类的金额消耗比例基本持平。结论肿瘤专科医院用药以抗肿瘤药及抗肿瘤辅助用药为主,疗效确切、毒副作用小、价格适中的抗肿瘤药具有良好的应用前景。 Objective To investigate the current status of drug usage for tumor treatment and to probe into the characteristic and the trend of drug utilization in a tumor hospital. Methods The data of drugs used for neoplasm treatment in our hospital during 2004-2006 were analyzed and compared by ranking the expenses. Results The amount of money used for tumor was ¥41.91, 52. 92, 52.44 million RMB in 2004, 2005 and 2006, respectively which accounted for 47. 0%, 55. 1%, 52. 15% of the total money spent on chemical drugs. The money used for antineoplastic agents in 2005 increased by 27.2% over 2004 , while decreased in 2006 because of decrease in prices. The money proportion of each sub-kind was basically equal over these 3 years. Conclusion The main drugs used in our hospital are antineoplastic agents and adjuvant drugs for tumor treatment. The antineoplastic agents with definite efficacy, low toxicity and moderate price has a good application prospect.
机构地区 湖南省肿瘤医院
出处 《中南药学》 CAS 2007年第3期279-282,共4页 Central South Pharmacy
关键词 抗肿瘤药 抗肿瘤辅助用药 购药金额 用药分析 antineoplastic agents adjuvant drugs for tumor treatment money for drugs analysis of drug utilization
  • 相关文献

参考文献7

二级参考文献62

  • 1郑子恢 潘慧杰.惠尔血对肿瘤放化疗所致白细胞减少症的临床观察[J].中国药学杂志,1998,33(12):713-713.
  • 2[5]Lebwohl D, Canetta R.Clinical development of platinum complexes in cancer therapy: an historical perspective and an update [J]. Eur J Cancer,1998,34(10):1 522.
  • 3[9]Uchida N, Takeda Y, Kasai H, et al. Antitumor efficacy of nedaplatin, a novel platinum complex,with cyclophosphamide in murine and human tumor model[J].Anticancer Res, 1998, 18(5A):3 375.
  • 4[10]Kawanishi K, Miyagi Y, Yamamoto J, et al. Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters[J]. Cancer Chemother Pharmacol,2001,47(4):303.
  • 5[11]Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin,tetraplatin, cisplatin and carboplatin: sepctrum of activity in drug-resistant cell lines and in the cell of the national cancer institutes anticancer drug screen panel[J]. Biochem Pharmacol, 1996,52(12): 1 855.
  • 6[13]Ferrante F, Winograd B, Canetta R.Promising new developments in cancer chemotherapy[J]. Cancer Chemother Pharmacol, 1999,43(suppl):61.
  • 7[14]Mckeage M J, Kelland L R, Boxall FE, et al. Schedule dependency of orally administered Bisacetatoamminedichioro-cyclohexyl amineplatinum (Ⅳ)(JM216)in vivo[J]. Cancer Res, 1994,54:4 118.
  • 8[15]Lloyd R Kelland. The development of orally active platinum drugs[C].In:Bemhard L. Chemistry and Biochemistry of a Leading Anticancer Drug .Zuri ch:Verl. Helvetica Chimica Acta ,Weinheim: Wiley VCH,1999:497 ~ 521.
  • 9[16]Desoize B,Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment [J]. Crit Rev Oncol Hematol, 2002, 42(3):317.
  • 10[17]Jakupec MA, Galanski M, Keppler BK.Tumour inhibiting platinum complexes-state of the art and future perspectives [J]. Rev Physiol Biochem Pharmacol,2003,146 : 1.

共引文献116

同被引文献18

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部